June 22, 2017 3:22 PM ET


Company Overview of Zynerba Pharmaceuticals, Inc.

Company Overview

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is...

80 West Lancaster Avenue

Suite 300

Devon, PA 19333

United States

Founded in 2007

12 Employees



Key Executives for Zynerba Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 58
Total Annual Compensation: $873.0K
Age: 58
Total Annual Compensation: $668.5K
Chief Financial Officer and Vice President of Corporate Development
Age: 52
Total Annual Compensation: $248.1K
Vice President of Human Resources, General Counsel and Secretary
Age: 59
Total Annual Compensation: $317.5K
Compensation as of Fiscal Year 2016.

Zynerba Pharmaceuticals, Inc. Key Developments

Zynerba Pharmaceuticals, Inc. Announces Enrollment Target of 16 Patients in Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) Clinical Trial Evaluating ZYN002 Cannabidiol (CBD) Gel in Children with Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS. Patients between the ages of 6 and 17 years with Fragile X syndrome have been enrolled in the exploratory FAB-C trial, which is designed to evaluate the safety and efficacy of ZYN002 CBD gel administered over a 12-week period in FXS. The study is evaluating 50 mg of CBD in ZYN002 4.2% gel once daily, which may be titrated up to 125 mg two times per day during the six-week titration period. Between weeks six and twelve, patients will receive a maintenance dose of 50 mg, 100 mg or 250 mg daily of CBD in ZYN002 4.2% gel. The primary outcome measures include changes in anxiety, depression and mood as measured by the ADAMS scale, a patient reported outcomes questionnaire that has been validated in FXS. Other measurements that are being observed include the Aberrant Behavior Checklist and visual analog scale (VAS) to assess for hyperactivity/impulsivity. Fragile X syndrome is an autism spectrum disorder and the most common inherited intellectual disability in males and a significant cause of intellectual disability in females. It is caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide). The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities, social anxiety and memory problems. In the US, there are about 71,000 patients suffering with FXS.

Zynerba Pharmaceuticals, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-08-2017 01:30 PM

Zynerba Pharmaceuticals, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-08-2017 01:30 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: James E. Fickenscher, Chief Financial Officer and Vice President of Corporate Development.

Zynerba Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2017

Zynerba Pharmaceuticals, Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $7,703,248,000, loss before income taxes of $7,259,021,000, net loss of $7,259,021,000, net loss per share - basic and diluted of $0.6,000 compared to the loss from operations of $4,241,869,000, loss before income taxes of $4,252,640,000, net loss of $4,281,374,000, net loss per share - basic and diluted of $0.49,000 for the same quarter a year ago.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zynerba Pharmaceuticals, Inc., please visit www.zynerba.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.